Companies do not have dedicated teams to monitor import/export and supply chain risks associated, finds survey

22 December 2020 (Last Updated December 22nd, 2020 07:31)

The COVID-19 pandemic has highlighted the vulnerability of pharmaceutical supply chains. Lockdowns and border closures left several pharmaceutical companies with limited access to key raw materials.

The COVID-19 pandemic has highlighted the vulnerability of pharmaceutical supply chains. Lockdowns and border closures left several pharmaceutical companies with limited access to key raw materials.

GlobalData has conducted a survey to assess how pharmaceutical companies are addressing and monitoring import/export and supply chain risks associated with coronavirus.

The respondent companies were broadly classified into three categories – companies without marketed drugs, companies with predominantly marketed drugs​, and companies with both pipeline and marketed drugs.

A majority 50% of the companies with both pipeline and marketed drugs opined that they do not have a dedicated team to address the risks, but they have committees/working teams that meet up regularly. Whereas 39% of the companies had a dedicated team and 11% depended on suppliers to identify the risks.

Among companies without marketed drugs, 47% depended on suppliers to identify the risks and 33% did not have a dedicated team to address the risks, while 20% had a dedicated team.

Import-export and supply chain risks

Monitoring of import/export risks by company type​

Approximately 36% of companies with both pipeline and marketed drugs had a dedicated team to manage the risks, while another 36% did not have a dedicated team and the remaining depended on suppliers to identify the risks.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.